BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32762776)

  • 1. The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation.
    Kosti A; de Araujo PR; Li WQ; Guardia GDA; Chiou J; Yi C; Ray D; Meliso F; Li YM; Delambre T; Qiao M; Burns SS; Lorbeer FK; Georgi F; Flosbach M; Klinnert S; Jenseit A; Lei X; Sandoval CR; Ha K; Zheng H; Pandey R; Gruslova A; Gupta YK; Brenner A; Kokovay E; Hughes TR; Morris QD; Galante PAF; Tiziani S; Penalva LOF
    Genome Biol; 2020 Aug; 21(1):195. PubMed ID: 32762776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
    Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
    Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the genetic and epigenetic landscape alterations in RNA binding proteins in glioblastoma.
    Bhargava S; Patil V; Mahalingam K; Somasundaram K
    Oncotarget; 2017 Mar; 8(10):16650-16668. PubMed ID: 28035070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Characterization of the RNA-Binding Protein SERBP1 Reveals Intrinsic Disorder and Atypical RNA Binding Modes.
    Baudin A; Moreno-Romero AK; Xu X; Selig EE; Penalva LOF; Libich DS
    Front Mol Biosci; 2021; 8():744707. PubMed ID: 34631798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
    Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
    Li Q; Dong C; Cui J; Wang Y; Hong X
    J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
    Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
    PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
    Chen X; Pan Y; Yan M; Bao G; Sun X
    Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
    Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
    Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    Mala U; Baral TK; Somasundaram K
    BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
    Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y
    Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.
    Maachani UB; Shankavaram U; Kramp T; Tofilon PJ; Camphausen K; Tandle AT
    Oncotarget; 2016 Nov; 7(47):77365-77377. PubMed ID: 27764801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications.
    Roura AJ; Szadkowska P; Poleszak K; Dabrowski MJ; Ellert-Miklaszewska A; Wojnicki K; Ciechomska IA; Stepniak K; Kaminska B; Wojtas B
    Clin Epigenetics; 2023 Feb; 15(1):29. PubMed ID: 36850002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
    Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
    PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Cover: Neutralization of terminal differentiation in gliomagenesis.
    Hu J; Ho AL; Yuan L; Hu B; Hua S; Hwang SS; Zhang J; Hu T; Zheng H; Gan B; Wu G; Wang YA; Chin L; DePinho RA
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14520-7. PubMed ID: 23918370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
    Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
    Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.
    Huang QR; Li JW; Pan XB
    Medicine (Baltimore); 2021 Dec; 100(48):e28065. PubMed ID: 35049227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells.
    Yi C; Li G; Ivanov DN; Wang Z; Velasco MX; Hernández G; Kaundal S; Villarreal J; Gupta YK; Qiao M; Hubert CG; Hart MJ; Penalva LOF
    RNA Biol; 2018; 15(11):1420-1432. PubMed ID: 30362859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.